Undeterred Capital
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Undeterred Capital.
Key people at Undeterred Capital.
Key people at Undeterred Capital.
# Undeterred Capital: Deep Tech Venture at the Intersection of Biology and Robotics
Undeterred Capital is a Los Angeles-based venture capital firm founded in late 2020 that specializes in early-stage investments in deep technology and bioscience companies[1][2]. The firm deploys capital in the range of $500K-$1M per investment, with over 80% of its portfolio concentrated at the pre-seed and seed stages[2]. Rather than waiting for companies to mature, Undeterred takes a hands-on approach, investing time alongside capital to help technical founders navigate the complex operational and commercialization challenges inherent to breakthrough science and technology ventures[2].
The firm's investment thesis centers on two primary domains: biological platforms (spanning material science, synthetic biology, and AI-driven drug discovery) and applied robotics (including autonomy, chemical automation, swarm robotics systems, and biomanufacturing)[2]. This dual focus reflects a conviction that the most transformative opportunities lie at the intersection of life sciences and advanced automation—sectors where technical risk, regulatory complexity, and market uncertainty demand both capital and strategic guidance.
Joe Wilson founded Undeterred Capital in late 2020 with a distinctive pedigree in deep tech entrepreneurship and venture investing[1]. Before launching the firm, Wilson co-founded and served as Chief Operating Officer of Multiply Labs, a pharma robotics company spun out of MIT in 2016[1]. Multiply raised capital from prominent investors including Y Combinator, Lux Capital, and Casdin Capital to develop robotic systems for cell and gene therapy manufacturing—a venture that gave Wilson firsthand experience in the challenges of commercializing cutting-edge biotechnology[1]. Following Multiply's exit, Wilson worked as a venture partner at MarsBio, an early-stage biotech venture firm, where he gained additional perspective on the venture ecosystem before deciding to launch his own fund[1].
The firm's operational infrastructure reflects deep expertise in venture finance. Paul Scott serves as Chief Financial Officer in a part-time capacity, bringing over 20 years of CFO experience across biotech venture firms[1]. Most notably, Scott has served as CFO at BioStar Ventures since 2006, managing a $200M fund, and previously held CFO roles at Windward Ventures, an $85M venture firm focused on early-stage investments in Southern California[1]. Scott has also served as interim CFO for multiple portfolio companies, including Network Harmoni (acquired by Micromuse) and Mohomine (acquired by Kofax), and previously served as CEO and Chairman of VSI Enterprises, a public company on NASDAQ[1]. This combination of venture operations expertise and portfolio company turnaround experience positions the firm to provide meaningful operational support beyond capital deployment.
Undeterred's primary differentiator is its willingness to invest at the earliest stages of company formation, with more than 80% of investments occurring at pre-seed or earlier[2]. This contrasts with many venture firms that wait for companies to demonstrate product-market fit before committing capital. By investing from incorporation forward, Undeterred positions itself as a foundational partner during the most uncertain phase of a startup's lifecycle[2].
The firm's dual focus on biological platforms and applied robotics reflects a thesis that breakthrough innovations increasingly emerge at the intersection of life sciences and advanced automation. This specialization allows the firm to develop deep domain expertise and network effects within these high-complexity sectors, where generalist investors may lack the technical acumen to evaluate opportunities effectively[2].
Rather than functioning as a passive capital provider, Undeterred explicitly positions itself as a partner that helps founders "solve their hardest operational and commercialization challenges"[2]. The team's collective experience—spanning MIT-derived deep tech entrepreneurship, biotech venture operations, and portfolio company turnarounds—enables the firm to provide guidance across technical risk, market risk, product risk, regulatory risk, scientific risk, and geopolitical risk[1]. This value-add model is particularly valuable for technical founders who may excel at innovation but lack business development and scaling experience.
The firm frequently leads or co-leads its investments, signaling conviction and enabling it to shape governance and strategic direction alongside founders[2]. This approach contrasts with smaller check sizes that often result in passive minority positions.
Undeterred Capital operates within a broader venture ecosystem increasingly focused on deep technology and climate-adjacent innovation. The firm's emphasis on biological platforms and applied robotics reflects several converging macro trends: the acceleration of synthetic biology and AI-driven drug discovery, the growing importance of automation in manufacturing (particularly in cell and gene therapy), and the venture community's recognition that breakthrough innovations in these domains require patient capital and operational expertise.
The timing of Undeterred's 2020 founding coincided with a period of significant capital inflow into biotech and deep tech venture investing, driven by both technological maturation and regulatory tailwinds (particularly in cell and gene therapy). By positioning itself at the pre-seed stage, the firm captures companies at the moment when academic breakthroughs are transitioning into commercial ventures—a critical juncture where the right operational guidance can dramatically improve success rates.
The firm's model also reflects a broader shift in venture capital toward value-add investing in complex technical domains. Rather than competing on brand or network alone, firms like Undeterred differentiate through deep domain expertise and hands-on operational support. This approach is particularly valuable in sectors like biotech and robotics, where regulatory complexity, manufacturing challenges, and scientific uncertainty create high failure rates among technically brilliant but operationally inexperienced founders.
Undeterred Capital is well-positioned to capture significant value as biological platforms and applied robotics mature from academic curiosities into commercial realities. The firm's founding team brings authentic credibility—Joe Wilson's experience building and scaling Multiply Labs provides a founder's perspective on the challenges these companies face, while Paul Scott's two decades in biotech venture operations ensures the firm can provide meaningful operational guidance.
The key question for Undeterred's evolution will be whether the firm can scale its model without diluting the hands-on support that differentiates it. As the firm deploys capital from its first fund (opened in April 2023), its ability to help portfolio companies navigate regulatory approval, manufacturing scale-up, and market entry will determine whether it becomes a marquee name in deep tech venture or remains a specialized player[6]. Given the structural tailwinds in synthetic biology, cell therapy manufacturing, and industrial robotics, and the scarcity of venture firms with both technical credibility and operational expertise in these domains, Undeterred appears well-positioned to build a durable, generational venture platform—precisely the outcome its founders are seeking to enable in their portfolio companies.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Aug 1, 2025 | EnsiliTech | $6.0M Seed | — | 7percent Ventures, Elbow Beach Capital |
| Jan 1, 2023 | EnsiliTech | $1.0M Seed | — | 7percent Ventures, Elbow Beach Capital |
